Heterologous prime–boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus

Vaccine

Volumn 36, Issue 24, 2018, Pages 3468-3476

  Jung, Seo Yeon ^a   Kang, Kyung Won ^b   Lee, Eun Young ^a   Seo, Dong Won ^b   Kim, Hong Lim ^c   Kim, Hak ^d   Kwon, TaeWoo ^d   Park, Hye Lim ^a   Kim, Hun ^d   Lee, Sang Myeong ^b   Nam, Jae Hwan ^a  

^a The Catholic University of Korea   (South Korea)

^b Chonbuk National University   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d Life Science Research Institute   (South Korea)

Author keywords

Adenovirus 5; Heterologous prime boost; MERS CoV; Th1; Th2; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; IMMUNOGLOBULIN G; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS VACCINE; NANOPARTICLE; SPIKE PROTEIN NANOPARTICLE; UNCLASSIFIED DRUG; VIRUS VACCINE; ALUMINUM POTASSIUM SULFATE; CORONAVIRUS SPIKE GLYCOPROTEIN; IMMUNOLOGICAL ADJUVANT; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

AFFINITY CHROMATOGRAPHY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOBLOTTING; LYMPHOCYTE ACTIVATION; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; VACCINATION; VIRUS STRAIN; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CHEMISTRY; CORONAVIRUS INFECTION; DRUG EFFECT; FEMALE; GENETICS; HUMAN; HUMAN ADENOVIRUS C; IMMUNIZATION; IMMUNOLOGY; PROCEDURES; SECONDARY IMMUNIZATION; VACCINE IMMUNOGENICITY; VIROLOGY;

ADENOVIRUSES, HUMAN; ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CORONAVIRUS INFECTIONS; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; IMMUNOGENICITY, VACCINE; IMMUNOGLOBULIN G; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NANOPARTICLES; SPIKE GLYCOPROTEIN, CORONAVIRUS; TH1 CELLS; TH2 CELLS; VIRAL VACCINES;

EID: 85046705063     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2018.04.082     Document Type: Article

References (43)

1. Chan, J.F.W., Lau, S.K.P., To, K.K.W., Cheng, V.C.C., Woo, P.C.Y., Yuen, K.Y., Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev 28:2 (2015), 465–522, 10.1128/CMR.00102-14.
2. Meyerholz, D.K., Lambertz, A.M., McCray, P.B. Jr., Dipeptidyl peptidase 4 distribution in the human respiratory tract. Am J Pathol 186:1 (2016), 78–86, 10.1016/j.ajpath.2015.09.014.
3. World Health Organization. Middle East respiratory syndrome coronavirus [MERS-CoV]; 2016. [accessed 20 August 2017].
4. Zumla, A., Chan, J.F.W., Azhar, E.I., Hui, D.S.C., Yuen, K.Y., Coronaviruses—drug discovery and therapeutic options. Nat Rev Drug Discov 15 (2016), 327–347, 10.1038/nrd.2015.37.
5. Wang, N., Shi, X., Jiang, L., Zhang, S., Wang, D., Tong, P., et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res 23:8 (2013), 986–993, 10.1038/cr.2013.92.
6. Coleman, C.M., Liu, Y.V., Mu, H., Taylor, J.K., Massare, M., Flyer, D.C., et al. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine 32 (2014), 3169–3174, 10.1016/j.vaccine.2014.04.016.
7. Wang, Q., Wong, G., Lu, G., Yan, J., Gao, G.F., MERS-CoV spike protein: targets for vaccines and therapeutics. Antiviral Res 133 (2016), 165–177, 10.1016/j.antiviral.2016.07.015.
8. Song, F., Fux, R., Provacia, L.B., Volz, A., Eickmann, M., Becker, S., et al. Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. J Virol 87 (2013), 11950–11954, 10.1128/JVI.01672-13.
9. Kim, E., Okada, K., Kenniston, T., Raj, V.S., AlHajri, M.M., Farag, E.A., et al. Immunogenicity of an adenoviral-based Middle East respiratory syndrome coronavirus vaccine in BALB/c mice. Vaccine 32 (2014), 5975–5982, 10.1016/j.vaccine.2014.08.058.
10. Guo, X., Deng, Y., Chen, H., Lan, J., Wang, W., Zou, X., et al. Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus. Immunology 145 (2015), 476–484, 10.1111/imm.12462.
11. Volz, A., Kupke, A., Song, F., Jany, S., Fux, R., Shams-Eldin, H., et al. Protective efficacy of recombinant modified vaccinia virus Ankara delivering Middle East respiratory syndrome coronavirus spike glycoprotein. J Virol 89:16 (2015), 8651–8656, 10.1128/JVI.00614-15.
12. Alharbi, N.K., Padron-Regalado, E., Thompson, C.P., Kupke, A., Wells, D., Sloan, M.A., et al. ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice. Vaccine 35 (2017), 3780–3788, 10.1016/j.vaccine.2017.05.032.
13. Du, L., Kou, Z., Ma, C., Tao, X., Wang, L., Zhao, G., et al. A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PLos ONE, 8, 2013, e81587, 10.1371/journal.pone.0081587.
14. Ma C, Li Y, Wang L, Zhao G, Tao X, Tseng CT, et al. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: implication for designing novel mucosal MERS vaccines. Vaccine 2014; 32(18):2100–8. doi: http://doi.org/10.1016/j.vaccine.2014.02.004.
15. Tang, J., Zhang, N., Tao, X., Zhao, G., Guo, Y., Tseng, C.T., et al. Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus. Hum Vaccin Immunother 11 (2015), 1244–1250, 10.1080/21645515.2015.1021527.
16. Zhang, N., Tang, J., Lu, L., Jiang, S., Du, L., Receptor-binding domain-based subunit vaccines against MERS-CoV. Virus Res 202 (2015), 151–159, 10.1016/j.virusres.2014.11.013.
17. Coleman, C.M., Venkataraman, T., Liu, Y.V., Glenn, G.M., Smith, G.E., Flyer, D.C., et al. MERS-CoV spike nanoparticles protect mice from MERS-CoV infection. Vaccine 35:12 (2017), 1586–1589, 10.1016/j.vaccine.2017.02.012.
18. Muthumani K, Falzarano D, Reuschel EL, Tingey C, Flingai S, Villarreal DO, et al. A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci Transl Med 2015; 7(301):301ra132. doi: http://doi.org/10.1126/scitranslmed.aac7462.
19. Wang, L., Shi, W., Joyce, M.G., Modjarrad, K., Zhang, Y., Leung, K., et al. Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun, 6, 2015, 7712, 10.1038/ncomms8712.
20. Naz, R.K., Dabir, P., Peptide vaccines against cancer, infectious diseases, and conception. Front Biosci 12 (2006), 1833–1844, 10.1586/14760584.2014.912134.
21. Cho, A., Seok, S.H., Ethical guidelines for use of experimental animals in biomedical research. J Bacteriol Virol 43 (2013), 18–26.
22. Zhao, J., Li, K., Wohlford-Lenane, C., Agnihothram, S.S., Fett, C., Zhao, J., et al. Rapid generation of a mouse model for Middle East respiratory syndrome. PNAS 111:13 (2014), 4970–4975, 10.1073/pnas.1323279111.
23. Singh, V.K., Mehrotra, S., Agarwal, S.S., The paradigm of Thl and Th2 cytokines. Immunol Res 20:3 (1999), 147–161.
24. Wang, R., Doolan, D.L., Le, T.P., Hedstrom, R.C., Coonan, K.M., Charoenvit, Y., et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282:5388 (1998), 476–480, 10.1126/science.282.5388.476.
25. Tatsis, N., Fitzgerald, J.C., Reyes-Sandoval, A., Harris-McCoy, K.C., Hensley, S.E., Zhou, D., et al. Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood 110 (2007), 1916–1923, 10.1182/blood-2007-02-062117.
26. Lindsay, R.W., Darrah, P.A., Quinn, K.M., Wille-Reece, U., Mattei, L.M., Iwasaki, A., et al. CD8+ T cell responses following replication-defective adenovirus serotype 5 immunization are dependent on CD11c+ dendritic cells but show redundancy in their requirement for TLR and nucleotide-binding oligomerization domain-like receptor signaling. J Immunol 185:3 (2010), 1513–1521, 10.4049/jimmunol.1000338.
27. Ahi, Y.S., Bangari, D.S., Mittal, S.K., Adenoviral vector immunity: its implications and circumvention strategies. Curr Gene Ther 11:4 (2011), 307–320.
28. Vogels, R., Zuijdgeest, D., van Rijnsoever, R., Hartkoorn, E., Damen, I., de Béthune, M.P., et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 77 (2003), 8263–8271, 10.1128/JVI.77.15.8263-8271.2003.
29. Barouch, D.H., Pau, M.G., Custers, J.H., Koudstaal, W., Kostense, S., Havenga, M.J., et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 172:10 (2004), 6290–6297, 10.4049/jimmunol.172.10.6290.
30. Shiver, J.W., Emini, E.A., Recent advances in the development of HIV-1 vaccines using replication incompetent adenovirus vectors. Annu Rev Med 55 (2004), 355–372, 10.1146/annurev.med.55.091902.104344.
31. Roberts, D.M., Nanda, A., Havenga, M.J., Abbink, P., Lynch, D.M., Ewald, B.A., et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441:7090 (2006), 239–243, 10.1038/nature04721.
32. Chillón, M., Lee, J.H., Fasbender, A., Welsh, M.J., Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro. Gene Ther 5 (1998), 995–1002, 10.1038/sj.gt.3300665.
33. Beer, S.J., Matthews, C.B., Stein, C.S., Ross, B.D., Hilfinger, J.M., Davidson, B.L., Poly [lactic-glycolic] acid copolymer encapsulation of recombinant adenovirus reduces immunogenicity in vivo. Gene Ter 5 (1998), 740–746, 10.1038/sj.gt.3300647.
34. Xiang, Z.Q., Gao, G.P., Reyes-Sandoval, A., Li, Y., Wilson, J.M., Ertl, H.C.J., Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J Virol 77:20 (2003), 10780–10789, 10.1128/JVI.77.20.10780-9.2003.
35. Croyle MA, Patel A, Tran KN, Gray M, Zhang Y, Strong JE, et al. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS ONE 3(10):e3548. doi: http://doi.org/10.1371/journal.pone.0003548.
36. Zhao J, Alshukairi AN, Baharoon SA, Ahmed WA, Bokhari AA, Nehdi AM, et al. Recovery from the Middle East respiratory syndrome is associated with antibody and T cell responses. Science 2017; 2(14):eaan5393. doi: http://doi.org/10.1126/sciimmunol.aan5393.
37. Tatsis, N., Lasaro, M.O., Lin, S.W., Haut, L.H., Xiang, Z.Q., Zhou, D., et al. Adenovirus vector-induced immune responses in nonhuman primates: responses to prime boost regimens. J Immunol 182:10 (2009), 6587–6599, 10.4049/jimmunol.0900317.
38. Harvey, B.G., Worgall, S., Ely, S., Leopold, P.L., Crystal, R.G., Cellular immune responses of healthy individuals to intradermal administration of an E1–E3- adenovirus gene transfer vector. Hum Gene Ther 10:17 (1999), 2823–2837, 10.1089/10430349950016555.
39. Santra, S., Seaman, M.S., Xu, L., Barouch, D.H., Lord, C.I., Lifton, M.A., et al. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J Virol 79:10 (2005), 6516–6522, 10.1128/JVI.79.10.6516-6522.2005.
40. Hoshino, T., Nakamura, H., Okamoto, M., Kato, S., Araya, S., Nomiyama, K., et al. Redox-active protein thioredoxin prevents proinflammatory cytokine- or bleomycin-induced lung injury. Am J Respir Crit Care med 1689:9 (2003), 1075–1083, 10.1164/rccm.200209-982OC.
41. Kim, H.W., Canchola, J.G., Brandt, C.D., Pyles, G., Chanock, R.M., Jensen, K., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89:4 (1969), 422–434, 10.1093/oxfordjournals.aje.a120955.
42. Hwang, H.S., Lee, Y.T., Kim, K.H., Park, S., Kwon, Y.M., Lee, Y., et al. Combined virus-like particle and fusion protein-encoding DNA vaccination of cotton rats induces protection against respiratory syncytial virus without causing vaccine-enhanced disease. Virology 494 (2016), 215–224, 10.1016/j.virol.2016.04.014.
43. Knudson, C.J., Hartwig, S.M., Meyerholz, D.K., Varga, S.M., RSV vaccine-enhanced disease is orchestrated by the combined actions of distinct CD4 T cell subsets. PLoS Pathog, 11(3), 2015, e1004757, 10.1371/journal.ppat.1004757.